Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli
03:32pm, Monday, 06'th Nov 2023
Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.
Final Trades: Freeport-McMoRan, Eli Lilly & Humana
02:07pm, Monday, 06'th Nov 2023
The "Halftime Report" traders give their top picks to watch for the second half.
Eli Lilly chief scientific officer ‘extremely optimistic' that major new Alzheimer's breakthrough is coming
11:05am, Monday, 06'th Nov 2023
Dr. Daniel Skovronsky believes a big leap in Alzheimer's disease treatment may be just around the corner–and that an overlooked class of medicines could become the GLP-1 drugs of the future.
The Importance of Brand Power: 3 Stocks to Consider
12:56pm, Friday, 03'rd Nov 2023
Brand power is real. The brand that consumers associate with a company is quantifiable and something valued.
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
12:47pm, Friday, 03'rd Nov 2023
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
05:51am, Friday, 03'rd Nov 2023
Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's.
Three-Stock Lunch: Eli Lilly, DoorDash and Target
03:31pm, Thursday, 02'nd Nov 2023
Eva Ados, ERShares CIO, joins 'Power Lunch' to discuss three stocks: Eli Lilly, DoorDash and Target.
Expect Eli Lilly's momentum to continue, says Bank of America's Geoff Meacham
02:40pm, Thursday, 02'nd Nov 2023
Geoff Meacham, Bank of America senior pharmaceutical analyst, joins 'The Exchange' to discuss Eli Lilly's performance, the demand outlook for weight loss drugs, and more.
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
01:16pm, Thursday, 02'nd Nov 2023
Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
12:02pm, Thursday, 02'nd Nov 2023
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare
Novo Nordisk, Eli Lilly stocks see boost on obesity drugs
11:26am, Thursday, 02'nd Nov 2023
Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozempic and Wegovy. Eli Lilly (LLY) shares also saw ga
Why Eli Lilly Stock Is Jumping Today
10:59am, Thursday, 02'nd Nov 2023
Lilly's Q3 revenue soared, but its earnings sank. However, the company's top- and bottom-line results handily beat Wall Street estimates.
Eli Lilly sees strong 3Q sales fueled by Mounjaro but cuts profit outlook
10:56am, Thursday, 02'nd Nov 2023
Eli Lilly and Co (NYSE:LLY) reported impressive third-quarter revenue as its diabetes drug Mounjaro exceeded sales expectations. The blockbuster drug generated quarterly sales of $1.41 billion, markin
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
08:10am, Thursday, 02'nd Nov 2023
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically
06:54am, Thursday, 02'nd Nov 2023
Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.
